tetano
Editor, Senior Moderator
J Infect Chemother. 2019 Mar 21. pii: S1341-321X(19)30064-9. doi: 10.1016/j.jiac.2019.02.022. [Epub ahead of print]
[h=1]Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus.[/h] Akashi Y[SUP]1[/SUP], Suzuki H[SUP]2[/SUP], Ueda A[SUP]3[/SUP], Hirose Y[SUP]4[/SUP], Hayashi D[SUP]5[/SUP], Imai H[SUP]6[/SUP], Ishikawa H[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recently, rapid molecular detection systems have been used for point-of-care testing for the diagnosis of influenza worldwide. Here, we evaluated the performance of the cobas Liat system and the cobas Influenza A/B assay (Liat) using fresh nasopharyngeal samples collected from a Japanese population between December 2017 and February 2018. The performance of the examination was compared with that of antigen testing and a conventional polymerase chain reaction (nested-PCR) method. A total of 159 patients were included in this study, and 77 tested positive using Liat. The concordance rate between Liat and nested PCR was 97.5%. The median time between the ordering of testing and completion of molecular analyses using Liat was 30 min (interquartile range: 28-35 min). The overall sensitivity and specificity of antigen testing were 57.1% and 100%, respectively. The duration from symptom onset to examination did not alter antigen testing sensitivity. The current study demonstrates the high performance of Liat for the rapid molecular identification of the influenza virus.
Copyright ? 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Cobas Influenza A/B; Cobas Liat system; Influenza; Point-of-care testing
PMID: 30905631 DOI: 10.1016/j.jiac.2019.02.022
[h=1]Analytical and clinical evaluation of a point-of-care molecular diagnostic system and its influenza A/B assay for rapid molecular detection of the influenza virus.[/h] Akashi Y[SUP]1[/SUP], Suzuki H[SUP]2[/SUP], Ueda A[SUP]3[/SUP], Hirose Y[SUP]4[/SUP], Hayashi D[SUP]5[/SUP], Imai H[SUP]6[/SUP], Ishikawa H[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recently, rapid molecular detection systems have been used for point-of-care testing for the diagnosis of influenza worldwide. Here, we evaluated the performance of the cobas Liat system and the cobas Influenza A/B assay (Liat) using fresh nasopharyngeal samples collected from a Japanese population between December 2017 and February 2018. The performance of the examination was compared with that of antigen testing and a conventional polymerase chain reaction (nested-PCR) method. A total of 159 patients were included in this study, and 77 tested positive using Liat. The concordance rate between Liat and nested PCR was 97.5%. The median time between the ordering of testing and completion of molecular analyses using Liat was 30 min (interquartile range: 28-35 min). The overall sensitivity and specificity of antigen testing were 57.1% and 100%, respectively. The duration from symptom onset to examination did not alter antigen testing sensitivity. The current study demonstrates the high performance of Liat for the rapid molecular identification of the influenza virus.
Copyright ? 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Cobas Influenza A/B; Cobas Liat system; Influenza; Point-of-care testing
PMID: 30905631 DOI: 10.1016/j.jiac.2019.02.022